Douglas R Moellering

Prof. Douglas R Moellering

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2015 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ZTZheng Tan
Zheng Tan
NXNa Xie
Na Xie
HCHuachun Cui
Huachun Cui
DMDouglas R Moellering
Douglas R Moellering
EAEdward Abraham
Edward Abraham
GLGang Liu
Gang Liu
The M1 and M2 polarized phenotypes dictate distinctive roles for macrophages as they participate in inflammatory disorders. There has been growing interest in the role of cellular metabolism in macrophage polarization. However, it is currently unclear whether different aspects of a specific metabolic program coordinately regulate this cellular process. In this study, we found that pyruvate dehydrogenase kinase 1 (PDK1), a key regulatory enzyme in glucose metabolism, plays an important role in the differential activation of macrophages. Knockdown of PDK1 diminished M1, whereas it enhanced M2 activation of macrophages. Mechanistically, PDK1 knockdown led to diminished aerobic glycolysis in M1 macrophages, which likely accounts for the attenuated inflammatory response in these cells. Furthermore, we found that mitochondrial respiration is enhanced during and required by the early activation of M2 macrophages. Suppression of glucose oxidation, but not that of fatty acids, inhibits this process. Consistent with its inhibitory role in early M2 activation, knockdown of PDK1 enhanced mitochondrial respiration in macrophages. Our data suggest that two arms of the glucose metabolism synergistically regulate the differential activation of macrophages. Our findings also highlight the central role of PDK1 in this event via controlling glycolysis and glucose oxidation.

26 July 2013 in Obesity
Verified
Journal Article
Open access
PDF file
Fangjian GuoFangjian Guo
Fangjian Guo
DMDouglas R Moellering
Douglas R Moellering
WGW. Timothy Garvey
W. Timothy Garvey
Objective: To validate a Cardiometabolic Disease Staging (CMDS) system for assigning risk level for diabetes, and all‐cause and cardiovascular disease (CVD) mortality.Design and Methods: Two large national cohorts, CARDIA and NHANES III, were used to validate CMDS. CMDS: Stage 0: metabolically healthy; Stage 1: one or two metabolic syndrome risk factors [other than impaired fasting glucose (IFG)]; Stage 2: IFG or impaired glucose tolerance (IGT) or metabolic syndrome (without IFG); Stage 3: two of three (IFG, IGT, and/or metabolic syndrome); and Stage 4: type 2 diabetes mellitus/CVD.Results: In the CARDIA study, compared with Stage 0 metabolically healthy subjects, adjusted risk for diabetes exponentially increased from Stage 1 [hazard ratio (HR) 2.83, 95% confidence interval (CI): 1.76‐4.55], to Stage 2 (HR 8.06, 95% CI 4.91‐13.2), to Stage 3 (HR 23.5, 95% CI 13.7‐40.1) (P for trend <0.001). In NHANES III, both cumulative incidence and multivariable adjusted HRs markedly increased for both all‐cause and CVD mortality with advancement of the risk stage from Stages 0 to 4. Adjustment for body mass index (BMI) minimally affected the risks for diabetes and all‐cause/CVD mortality using CMDS.Conclusion: CMDS can discriminate a wide range of risk for diabetes, CVD mortality, and all‐cause mortality independent of BMI, and should be studied as a risk assessment tool to guide interventions that prevent and treat cardiometabolic disease.

1 October 2004 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
DDDale A. Dickinson
Dale A. Dickinson
ALAnna-liisa Levonen
Anna-liisa Levonen
DMDouglas R Moellering
Douglas R Moellering
EAErin K. Arnold
Erin K. Arnold
HZHongqiao Zhang
Hongqiao Zhang
HFHenry Forman
Henry Forman

1 June 2000 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
RPRakesh P. Patel
Rakesh P. Patel
DMDouglas R Moellering
Douglas R Moellering
JMJoanne Murphy-Ullrich
Joanne Murphy-Ullrich
HJHanjoong Jo
Hanjoong Jo
JBJoseph S Beckman
Joseph S Beckman
VDVictor Darley-Usmar
Victor Darley-Usmar

9 September 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
COClaudia R. Oliva
Claudia R. Oliva
DMDouglas R Moellering
Douglas R Moellering
GGG. Yancey Gillespie
G. Yancey Gillespie
CGCorinne E. Griguer
Corinne E. Griguer
Temozolomide (TMZ) is an alkylating agent used for treating gliomas. Chemoresistance is a severe limitation to TMZ therapy; there is a critical need to understand the underlying mechanisms that determine tumor response to TMZ. We recently reported that chemoresistance to TMZ is related to a remodeling of the entire electron transport chain, with significant increases in the activity of complexes II/III and cytochrome c oxidase (CcO). Moreover, pharmacologic and genetic manipulation of CcO reverses chemoresistance. Therefore, to test the hypothesis that TMZ-resistance arises from tighter mitochondrial coupling and decreased production of reactive oxygen species (ROS), we have assessed mitochondrial function in TMZ-sensitive and -resistant glioma cells, and in TMZ-resistant glioblastoma multiform (GBM) xenograft lines (xenolines). Maximum ADP-stimulated (state 3) rates of mitochondrial oxygen consumption were greater in TMZ-resistant cells and xenolines, and basal respiration (state 2), proton leak (state 4), and mitochondrial ROS production were significantly lower in TMZ-resistant cells. Furthermore, TMZ-resistant cells consumed less glucose and produced less lactic acid. Chemoresistant cells were insensitive to the oxidative stress induced by TMZ and hydrogen peroxide challenges, but treatment with the oxidant L-buthionine-S,R-sulfoximine increased TMZ-dependent ROS generation and reversed chemoresistance. Importantly, treatment with the antioxidant N-acetyl-cysteine inhibited TMZ-dependent ROS generation in chemosensitive cells, preventing TMZ toxicity. Finally, we found that mitochondrial DNA-depleted cells (ρ°) were resistant to TMZ and had lower intracellular ROS levels after TMZ exposure compared with parental cells. Repopulation of ρ° cells with mitochondria restored ROS production and sensitivity to TMZ. Taken together, our results indicate that chemoresistance to TMZ is linked to tighter mitochondrial coupling and low ROS production, and suggest a novel mitochondrial ROS-dependent mechanism underlying TMZ-chemoresistance in glioma. Thus, perturbation of mitochondrial functions and changes in redox status might constitute a novel strategy for sensitizing glioma cells to therapeutic approaches.

28 June 2006 in Neuropsychopharmacology
Verified
Journal Article
Closed access
HVHelliner S Vestri
Helliner S Vestri
LMLidia Maianu
Lidia Maianu
DMDouglas R Moellering
Douglas R Moellering
WGW Timothy Garvey
W Timothy Garvey